Alnylam chalks up another win with trial of a liver-disease drug – STAT
The drug, based on RNA interference technology, silences a gene critical to the development of damaging and painful kidney stones.
Related Articles
Express Scripts overcharged postal workers by $45 million, audit says
Express Scripts, one of the largest PBMs in the country, overcharged U.S. Postal Service employees by $45 million for their prescription drugs, a federal audit…
At a Mass General perfusion lab, a push to make more and more hearts viable for transplant
It seems like organized chaos. Five lab members move around a room the size of a galley kitchen. On this day, three high school students…
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
How UnitedHealth harnesses its physician empire to squeeze profits out of patients
The insurer UnitedHealth is using its unrivaled physician empire to enrich itself by milking Medicare Advantage.
How Kamala Harris’ views on health care were shaped by her mother, cancer researcher Shyamala Gopalan
Kamala Harris’ late mother, the prominent breast cancer researcher Shyamala Gopalan, helped shape the presidential candidate’s views on health and medicine.
The worst for Dexcom may not be over
Shares of Dexcom plummeted nearly 40% in post-market trading yesterday, after the company lowered its full-year sales guidance. The maker of continuous glucose monitors is…
Pharmalittle: We’re reading about a thumbs down for an Alzheimer’s drug, Pfizer gene therapy struggles, and more
A European Medicines Agency committee that evaluates new drugs recommended that Leqembi, an Alzheimer’s therapy from Eisai and Biogen, should be rejected.
Medtech compliance — not regulation — is stifling innovation
To transform compliance from a red tape burden to a real guardrail, medtech companies should adopt developer-first approaches like shift-left testing.
European regulators say Alzheimer’s therapy Leqembi should be rejected
European regulators said that an Alzheimer’s therapy from Eisai and Biogen should be rejected, diverging from their U.S. counterparts, who have approved the medicine.
How Pfizer’s grand gene therapy ambitions crumbled
Pfizer, which reported data on a gene therapy this for hemophilia week, once had much bigger ambitions in the field. What happened?